The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The company anticipates that top-line efficacy and safety data analyses from the studies will be reported in August 2008.
Declan Daly, CEO of Isolagen, said: “The completion of the pivotal efficacy portion of our Phase III clinical studies is a major milestone for Isolagen. I commend the Isolagen team and our investigators for their efforts and look forward to announcing the data once it is un-blinded later this summer.”